Form 4: Arrowhead COO O'Brien Gifts Shares, Receives RSU Grant

Arrowhead Pharmaceuticals COO Patrick O'Brien reported gifting 2,500 shares of common stock and receiving a grant of 75,000 restricted stock units.

Summary

• Patrick O'Brien, Chief Operating Officer (COO) of Arrowhead Pharmaceuticals, Inc. (ARWR), reported transactions on January 6, 2026.
• O'Brien gifted a total of 2,500 shares of common stock to relatives across five separate transactions, each at a price of $0.
• Following these gifts, O'Brien's direct beneficial ownership of common stock was 472,408 shares.
• O'Brien also acquired 75,000 shares underlying restricted stock units (RSUs) at a price of $0.
• These 75,000 RSUs will vest in four equal annual installments.
• After all reported transactions, O'Brien's direct beneficial ownership of common stock, including RSUs subject to vesting, stands at 547,408 shares.

Sentiment

Score: 6

Explanation: The grant of 75,000 restricted stock units to the COO is a positive sign of continued executive alignment and compensation, outweighing the minor personal gifts of shares.

Positives

• The COO received a significant grant of 75,000 restricted stock units, aligning his interests with long-term shareholder value.

Negatives

• The COO gifted 2,500 shares of common stock, reducing his direct beneficial ownership by that amount.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Patrick O'Brien gifted 2,500 shares of common stock to relatives.

Stakeholder Impact

• Shareholders: The RSU grant aligns the COO's long-term interests with shareholder value. The gifted shares represent a minor change in outstanding shares.
• Employees: The RSU grant is part of executive compensation, which can influence overall compensation philosophy within the company.

Next Steps

• The 75,000 restricted stock units will vest in four equal annual installments, indicating future share issuances to the COO.

Key Dates

Recommendation

This Form 4 primarily details routine executive compensation (RSU grant) and personal financial planning (gifts). While the RSU grant is a positive for executive alignment, these transactions are not significant enough to warrant a change in investment recommendation for Arrowhead Pharmaceuticals based solely on this filing. Investors should continue to hold based on broader company fundamentals and market conditions.

Keywords

Arrowhead Pharmaceuticals, ARWR, Patrick O'Brien, COO, Insider Transaction, Form 4, Restricted Stock Units, RSU Grant, Stock Gift, Beneficial Ownership, Executive Compensation